This case illustrates that trastuzumab deruxtecan (T-DXd) can provide meaningful clinical benefit in an elderly, frail patient with hormone receptor–positive (HR+)/HER2-low breast cancer and malignant pleural effusion, even though the recurrent biopsy was HER2-0. This evidence concerns the gene ERBB2 and breast cancer.